Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Common Equity: 2019-2024

Historic Common Equity for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to $510.6 million.

  • 4D Molecular Therapeutics' Common Equity fell 33.27% to $369.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $369.0 million, marking a year-over-year decrease of 33.27%. This contributed to the annual value of $510.6 million for FY2024, which is 65.87% up from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Common Equity of $510.6 million as of FY2024, which was up 65.87% from $307.8 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Common Equity peaked at $510.6 million during FY2024, and registered a low of $231.3 million during FY2022.
  • Its 3-year average for Common Equity is $349.9 million, with a median of $307.8 million in 2023.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Common Equity soared by 451.36% in 2020 and then fell by 27.50% in 2022.
  • Yearly analysis of 5 years shows 4D Molecular Therapeutics' Common Equity stood at $256.4 million in 2020, then grew by 24.46% to $319.1 million in 2021, then dropped by 27.50% to $231.3 million in 2022, then skyrocketed by 33.07% to $307.8 million in 2023, then spiked by 65.87% to $510.6 million in 2024.